Dyskinesia Pipeline Assessment (2022): In-depth Analysis of Clinical Trials, Latest FDA, EMA, and PMDA Approvals, Emerging Drugs, Growth Prospects, and Key Companies by DelveInsight

DelveInsight's Dyskinesia Pipeline Insight 2022 report provides comprehensive insights about 40+ companies and 45+ pipeline drugs in the Dyskinesia pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, mechanism of action, and molecule type. It further highlights the inactive pipeline products in this space.

Dyskinesia Overview
Dyskinesia is a movement disorder that often appears as uncontrolled shakes, tics, or tremors. Often, the condition occurs in people with Parkinson's disease due to the overstimulation of their dopamine receptors from medications that increase this neurotransmitter in the brain. One common example of a Parkinson's medication that can have this effect is levodopa. Another type of dyskinesia is tardive dyskinesia, which occurs when a person takes certain dopamine receptor-blocking medications.

In many cases, dyskinesia treatment involves addressing the underlying cause. Often, a doctor will not treat the condition unless the person's symptoms are severe. If it is severe and the cause is a disorder, infection, or injury to the brain, then doctors will treat them.

Some of the key takeaways from the Dyskinesia Pipeline Report https://www.delveinsight.com/report-store/dyskinesia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

• Companies across the globe are diligently working toward developing novel Dyskinesia treatment therapies with a considerable amount of success over the years. Dyskinesia Key players such as - Contera Pharma, VistaGen Therapeutics, Inc., Neurolixis, Celon Pharma, Addex Therapeutics, IRLAB Therapeutics AB, MAPLIGHT THERAPEUTICS, Melior Pharmaceuticals, Molomics, PharmaTher, Integrative Research Laboratories AB, Teva Branded Pharmaceutical, Luye Pharma Group, Ultragenyx Pharmaceutical Inc, IMAC holdings, Neurocrine Biosciences, Inc., PolyCore, Texas Biomedical Research Institute, ReCode Therapeutics, SOM Biotech, and others, are developing therapies for the Dyskinesia treatment
• Dyskinesia Emerging therapies such as CP 011, PCT-3012, Mesocarb, ML 007, LY 03015, JM-010, NLX 112, CPL 500036, and others are expected to have a significant impact on the Dyskinesia market in the coming years.
• In April 2019, Bukwang Pharmaceutical initiated a trial titled, "A Randomized, Double-Blind, Placebo-Controlled, Two-Part Study in Parkinson's Disease Patients With Dyskinesia to Assess the Efficacy and Safety/Tolerability of Fixed Dose Combinations of JM-010 and Its Individual Components"
• In July 2019, Contera Pharma initiated a trial titled, "A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study in Parkinson's Disease Patients With Moderate to Severe Dyskinesia to Assess the Efficacy and Safety/Tolerability of Two Dose Combinations of JM-010"
• In February 2020, Bukwang received the investigational new drug (IND) clearance from the US Food and Drug Administration (FDA) to proceed with the phase II clinical study of JM-010. JM-010, originating from a Danish bio venture company Contera Pharma, is currently under development for treating dyskinesia which emerges in up to 90% of Parkinson's disease patients following long-term treatment of levodopa

Dyskinesia Pipeline Therapeutics Assessment
The Dyskinesia Pipeline report proffers an integral view of the Dyskinesia emerging novel therapies segmented by Stage, Product Type, Molecule Type, Mechanism of Action, and Route of Administration.

Some of the key takeaways from the Dyskinesia Pipeline Report https://www.delveinsight.com/sample-request/dyskinesia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Dyskinesia Pipeline Clinical Phases:
DelveInsight's Report covers around 45+ products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Emerging Dyskinesia Drugs Under Different Phases of Clinical Development Include:
• CP 011: Contera Pharma
• PCT-3012: PolyCore Therapeutics
• Mesocarb: Melior Pharmaceuticals
• ML 007: MapLight Therapeutics
• LY 03015: Luye Pharma Group
• JM-010: Contera Pharma
• NLX 112: Neurolixis
• CPL 500036: Celon Pharma

Dyskinesia Pipeline Analysis
The Dyskinesia pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the Dyskinesia treatment with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Dyskinesia Treatment.
• Dyskinesia key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Dyskinesia Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the Dyskinesia market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Further Dyskinesia product details are provided in the report. Download the Dyskinesia pipeline report to learn more about the emerging Dyskinesia therapies at:
https://www.delveinsight.com/sample-request/dyskinesia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Dyskinesia Pipeline Market Drivers
• Increase in the prevalence of Dyskinesia
• Increase in the demand for disease-specific novel Dyskinesia treatment

Dyskinesia Pipeline Market Barriers
• Lack of understanding of the pharmacology of Dyskinesia
• Side-effects associated with drugs

Get a Free Sample PDF Report to know more about Vitiligo Pipeline Assessment- https://www.delveinsight.com/sample-request/dyskinesia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Scope of Dyskinesia Pipeline Drug Insight
• Coverage: Global
• Key companies in the Dyskinesia Therapeutics Market: Contera Pharma, VistaGen Therapeutics, Inc., Neurolixis, Celon Pharma, Addex Therapeutics, IRLAB Therapeutics AB, MAPLIGHT THERAPEUTICS, Melior Pharmaceuticals, Molomics, PharmaTher, Integrative Research Laboratories AB, Teva Branded Pharmaceutical, Luye Pharma Group, Ultragenyx Pharmaceutical Inc, IMAC holdings, Neurocrine Biosciences, Inc., PolyCore, Texas Biomedical Research Institute, ReCode Therapeutics, SOM Biotech, and others
• Key Dyskinesia Therapies: CP 011, PCT-3012, Mesocarb, ML 007, LY 03015, JM-010, NLX 112, CPL 500036, and others
• Dyskinesia Therapeutic Assessment: Dyskinesia current marketed and Dyskinesia emerging therapies
• Dyskinesia Market Dynamics: Dyskinesia market drivers and Dyskinesia market barriers

Request for Sample PDF Report for Dyskinesia Pipeline Assessment https://www.delveinsight.com/sample-request/dyskinesia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Table of Contents
1 Dyskinesia Report Introduction
2 Dyskinesia Executive Summary
3 Dyskinesia Overview
4 Dyskinesia- Analytical Perspective In-depth Commercial Assessment
5 Dyskinesia Pipeline Therapeutics
6 Dyskinesia Late Stage Products (Phase II/III)
7 Dyskinesia Mid Stage Products (Phase II)
8 Dyskinesia Early Stage Products (Phase I)
9 Dyskinesia Preclinical Stage Products
10 Dyskinesia Therapeutics Assessment
11 Dyskinesia Inactive Products
12 Company-University Collaborations (Licensing/Partnering) Analysis
13 Dyskinesia Key Companies
14 Dyskinesia Key Products
15 Dyskinesia Unmet Needs
16 Dyskinesia Market Drivers and Barriers
17 Dyskinesia Future Perspectives and Conclusion
18 Dyskinesia Analyst Views
19 Appendix
20 About DelveInsight

Download Sample PDF Report to know more about Dyskinesia drugs and therapies- https://www.delveinsight.com/sample-request/dyskinesia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Related Reports:
Dyskinesia Market https://www.delveinsight.com/report-store/dyskinesia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

DelveInsight's 'Dyskinesia-Market Insights, Epidemiology, and Market Forecast-2032' report delivers an in-depth understanding of the 7MM, historical and forecasted epidemiology as well as the 7MM market trends in the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom),

Dyskinesia Epidemiology https://www.delveinsight.com/report-store/dyskinesia-epidemiology-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

DelveInsight's 'Dyskinesia Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted Cholangiocarcinoma epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Trending Reports:

Diagnostic Imaging Equipment Market
https://www.delveinsight.com/report-store/diagnostic-imaging-equipment-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Diagnostic Imaging Equipment Market By Product (X-Ray Imaging Systems, Computed Tomography (CT) Scanners, Ultrasound Systems, Magnetic Resonance Imaging (MRI) Systems, Nuclear Imaging Systems, Mammography Systems, And Others), By Application (Cardiology, Oncology, Gastroenterology, Gynecology, And Other Applications), By End-User (Hospitals, Diagnostic Imaging Centres, And Others), by geography is expected to grow at a steady CAGR forecast till 2026 owing to rising technological advancement and increasing prevalence of chronic diseases.


Invasive Candidiasis Market
https://www.delveinsight.com/report-store/invasive-candidiasis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

"DelveInsight's 'Invasive Candidiasis Market Insight, Competitive Landscape and Market Forecast, 2027' report delivers an in-depth understanding of Invasive Candidiasis and the historical and forecasted Invasive Candidiasis market trends, globally, which comprises of North America, Europe, APAC, and RoW.


Sialidosis Market
https://www.delveinsight.com/report-store/sialidosis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

DelveInsight's "Sialidosis Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Sialidosis, historical and forecasted epidemiology, and the Sialidosis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Filgrastim Biosimilar Insight
https://www.delveinsight.com/report-store/filgrastim-biosimilar-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

DelveInsight's, "Filgrastim Biosimilar Insight, 2022," report provides comprehensive insights about 20+ companies and 20+ marketed and pipeline drugs in the Filgrastim Biosimilars landscape. It covers the marketed and pipeline drug profiles, including clinical and non-clinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Pain Management Devices Market
https://www.delveinsight.com/report-store/pain-management-devices-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Pain Management Devices Market By Type Of Devices (Neuromodulation & Neurostimulation Devices, Analgesic Infusion Pumps [Intrathecal Infusion Pumps and External Infusion Pumps], Ablation Devices [Radiofrequency Ablation Devices And Cryoablation Devices], And Others), By Application (Neuropathic Pain, Cancer Pain, Facial & Migraine Pain, Musculoskeletal Pain, and Others), By Geography is expected to grow at a steady CAGR Forecast till 2027

To know more about our Competitive Services, Click here:
https://www.delveinsight.com/consulting/competitive-intelligence-services?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Contact Us:
Gaurav Bora
gbora@delveinsight.com
+1(919)321-6187
www.delveinsight.com

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

This release was published on openPR.